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Abstract
Background and Objectives: Expandable distal femur prostheses have become more
popular over the last decades, but scientific data is limited.
Methods: A retrospective study was performed, including cases treated between
1986 and 2019 in 15 European referral centers for bone sarcomas.
Results: A total of 299 cases were included. Average follow‐up was 80 months
(range, 8‐287 months). Mean patient age was 10 years. Most (80%) of the implants
were noninvasive growers and a fixed hinge knee was used more often (64%) than a
rotating hinge. Most prosthetic designs showed good (>80%) implant survival at
10 years, but repeat surgery was required for 63% of the patients. The most fre-
quent reason for revision procedure was the completion of lengthening potential.
Noninvasive expandable implants showed less risk of infection compared to invasive
growers (11.8% vs 22.9% at 10 years). No difference in aseptic loosening was found
between cemented and uncemented stems.
Conclusions: This study shows the increasing popularity of expandable distal femur
prostheses, with overall good results for function and implant survival. However,
repeat surgery is frequently required, especially in patients under the age of
10 years old. Infection is less frequent in noninvasive growers compared to implants
that require invasive lengthening procedures.
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1 | BACKGROUND
Expandable prostheses have become an important reconstructive
technique in the treatment of children with bone sarcomas of the
lower limb. According to a recent survey by the European Muscu-
loskeletal Oncology Society (EMSOS), more than 60% of orthopedic
oncologists have used this technique.1 However, less than 5% of
these consultants have implanted more than five expandable pros-
theses. Therefore, scientific data on these implants remains limited.
The current literature includes mainly small series, or mono‐
institutional studies with inevitable selection bias.2‐8 According to
these reports, complications are relatively common and outcome is
difficult to predict compared to adult‐type megaprostheses.
We, therefore, performed an international EMSOS study on ex-
pandable prostheses of the distal femur. The objective of this study
was to increase scientific data on this type of reconstruction, to
provide patients with reliable information on indications, complica-
tions, functional outcome, and need for further surgery.
2 | METHODS
All members of the European Musculoskeletal Oncology Society
were invited to participate to this study by sending in data on their
cases of expandable reconstructions of the distal femur. Cases were
included regardless of patient age, indication, and expansion me-
chanism. The study period was between 1986 and 2019. All com-
plications requiring further surgery were recorded and classified
according to Henderson et al.9
At final follow‐up, functional results of surviving patients with
implant in situ were evaluated according to the Musculoskeletal
Tumor Society (MSTS) Score. Limb‐length discrepancy was evaluated
on panoramic radiographs of the lower limbs at final follow‐up.10
The Kaplan‐Meier method was used to estimate overall survival
(OS) of the implant. The implant failure rate was defined as the re-
moval of the expandable prosthesis for any reason, and it was calcu-
lated by competing risk analysis with expandable prosthesis censored
at the time of failure or last follow‐up. Infection free and amputation
free‐rates were also calculated by Kaplan‐Meier survival analysis.
Categorical variables were compared between groups by contingency
tables and chi‐square test. Significance was set with P values <.05 in
all statistical analyses, which were completed using the Statistical
Package for Social Science (IBM Corp. Released 2013. IBM SPSS
Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp).
3 | RESULTS
A total of 299 cases were included from 15 different referral centers
for orthopedic oncology in 9 different European countries (Italy, the
Netherlands, Belgium, France, United Kingdom, Austria, Russia,
Ukraine, Israel). Before the year 2000, expandable prostheses were
very rarely used, with an annual incidence of less than four implants
per year. After the year 2000 there was a quick increase in the number
of implants. Since 2010, there is a slow but gradual increase of the
yearly implanted distal femoral expandable prostheses according to
the data sent in by the participating EMSOS centers (Figure 1).
Median follow‐up in this study was 80 months (range,
8‐287 months). The mean age of patients at the time of surgery was
10 years (range, 4‐63 years). The most frequent diagnosis was os-
teosarcoma, in 271 (90.6%) patients, followed by Ewing sarcoma in
20 (6.7%) patients. Other diagnoses were chondrosarcoma (two pa-
tients), undifferentiated pleomorphic sarcoma (two patients), and
secondary bone loss due to prosthetic loosening (three patients) or
infection (one patient). The average tumor size (length) was 117mm
(range, 35‐238mm).
Fifty‐two (17.4%) patients had metastatic disease at the time of
diagnosis. All but six patients underwent (neo‐)adjuvant chemother-
apy. A total of eleven patients received also radiotherapy for the
primary tumor. At the final follow‐up, 76% of the tumor patients had
no evidence of disease.
Sixty (20%) of the implants required (mini‐)invasive surgical pro-
cedures for lengthening, the remainder were noninvasive growers. In
almost two thirds (64%) of the cases, a fixed hinge joint mechanism
was implanted, the others received a rotating hinge prosthesis.
More than half of the prostheses (53%) in this database, were
manufactured by Stanmore Implants Worldwide (Elstree, UK). Other
frequently used implants were manufactured by Stryker/Howmedica
(Mahwah), Implantcast (Buxtehude, Germany) and Wright Medical
Technology (Arlington) (Table 1).
Complications were classified according to the modified Hen-
derson classification of implant failure.9 The most frequent reason for
revision procedure in this database was the completion of length-
ening potential, which was considered a pediatric failure (Table 2).
Kaplan‐Meier survival analysis of invasive vs noninvasive grow-
ing prostheses against infection, showed significantly (P = .015)
F IGURE 1 Expandable distal femoral prostheses implanted per
year, according to the EMSOS database [Color figure can be viewed
at wileyonlinelibrary.com]
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higher risk of infection for the implants that required a surgical
procedure for lengthening (Figure 2) (88.2% vs 77.1% at 10 years).
Cemented and uncemented stems, had a comparable survival;
aseptic loosening was seen respectively in 19.6% and 13.7% at
10 years (P = .394) (Figure 3).
There was no statistically significant difference in implant
survival between fixed hinge and rotating hinge systems (P = .526).
Total length achievement was more often reason for implant
revision in young children (Figure 4). The revision rate was 37.3% in
patients up to 10 years of age, and 23.6% in those older than
10 (P = .047).
The Wright prostheses showed worse survival (57.9% at 5 years
and 40.9% at 10 years), when looking at mechanical implant failure
(type 2 and 3). The Stanmore, Stryker and Implantcast prostheses all
had an implant survival of more than 80% at 5 and 10 years
(Figure 5).
At the final follow‐up, sixty‐eight percent of the patients had an
expandable implant in situ. For 194 patients, information was avail-
able on limb length compared to the opposite limb. Sixty‐seven of
these had no limb length discrepancy (LLD) at the final follow‐up. For
the remaining 127 patients the LLD was on average 23mm (range,
4‐87mm). A total of 23 patients underwent a contralateral epiphy-
siodesis of at least one of the growth plates around the knee. The
average MSTS score was 25 (range, 9‐30). Excluding mini‐invasive
lengthening procedures, one hundred and eighty‐eight (63%) patients
required further surgery, and an average of 2.2 surgeries per patient
were performed during the study period. Also, 12% (36 patients)
developed a deep infection of the expandable prosthesis during
follow‐up, and a total of 20 patients (7%) required demolitive
surgery.
4 | DISCUSSION
Expandable distal femoral replacements have been used since the
70 seconds, when limb salvage surgery started to become more
TABLE 1 Implants manufacturers
Prosthesis manufacturer Nr (%)
Implantcast 43 (14%)
Wright 38 (13%)
Stanmore 157 (53%)
Stryker/Howmedica 48 (16%)
Other 13 (4%)
TABLE 2 Complications
Complication Number of surgeries
Soft tissue complications 35
Aseptic loosening 70
Structural failure 62
Infection 61
Tumor progression 20
Pediatric failures 102
F IGURE 2 Implant survival of invasive vs
noninvasive prosthesis against infection showed
better outcome for non‐invasive expandable
implants [Color figure can be viewed at
wileyonlinelibrary.com]
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frequent and required special reconstructions in children to over-
come the problem of growth loss. However, the early expandable
prosthetic designs showed disappointing results, and required mul-
tiple invasive surgeries.4,11,12 For this reason, expandable
reconstructions were rarely used before the end of the 21st century.
Since the introduction of noninvasive expandable implants, the po-
pularity of this reconstructive technique has increased significantly.
This study showed how the incidence of this indication raised almost
F IGURE 3 Implant survival of cemented vs
uncemented stem fixation did not show a
significant difference [Color figure can be viewed
at wileyonlinelibrary.com]
F IGURE 4 Children up to 10 years had
significantly higher risk for revision surgery due
to completion of total length potential [Color
figure can be viewed at wileyonlinelibrary.com]
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exponentially since the year 2000, and is still increasing, although at
a slower rate, over the last decade. Reason for this, is certainly the
improved implant design, with higher mechanical reliability and lower
infection risk for the most recent generation of expandable
implants.3,5,8,13
In the current database, which represents the largest series of
expandable distal femoral prostheses, the mean age of patients was
10 years. This is similar to data reported in the previous series of
expandable implants.3,5,8,13 Very young patients, under the age of 5
or 6 years, require a lengthening potential that is difficult to obtain
with a single expandable implant. Furthermore, at this age, a reliable
implant fixation is very challenging due to the small diameter and
length of the residual femur after tumor resection. For this reason,
amputation and rotationplasty are thought to be valid alternatives
for patients in this very young age group. At the same time, for
pediatric patients who are close to skeletal maturity, an expandable
implant is often not necessary. For these patients, the limited loss of
growth potential can be easily compensated by less invasive and less
expensive measures such as a shoe lift, overlengthening with a
modular non‐expandable implant, and contralateral epiphysiodesis.14
Over the years, there has been a tendency to reduce the inva-
siveness of the lengthening procedures and the most recently in-
troduced implants are all noninvasive growers. This study confirms
the theoretical advantage of noninvasive growers over invasive
growers, with significantly less infections in the first group.
In this database, the Stanmore JTS prosthesis was the most popular
expandable distal femoral implant. This specific implant has the ad-
vantage of a noninvasive lengthening mechanism. Stem fixation is either
cemented or uncemented and the hinge mechanism can be either fixed
or rotating. In the previous series, this implant has shown reliability of
the lengthening mechanism in an outpatient setting and overall implant
survival was relatively high.5,8,13 Also in the current study, the Stanmore
expandable implant showed good overall survival. Both, Stryker and
Implantcast expandable prostheses showed similar durability to that of
the Stanmore implants and no statistical difference in implant survival
could be detected between these implants in the current study. How-
ever, this analysis confirmed a poor implant survival for the Wright
prosthesis, as was reported in previous series.15
Stem fixation for megaprosthesis in children remains a con-
troversial issue. In this database, we did not find a significant dif-
ference for aseptic loosening, when comparing cemented and
uncemented stem fixation. However, as most patients in this series
required further major revision surgery during follow‐up, it is im-
portant to take into consideration the loss of bone stock during fu-
ture stem revisions, as well as the risk for stress shielding in pediatric
patients, in the decision‐making process on stem choice and fixation.
The most frequent reason for implant revision in this study was
completion of the lengthening potential. Whether this is a real
complication remains questionable, as this event is often predictable
in young children who are reconstructed with implants that have a
limited lengthening potential. However, it is a reason for major re-
vision surgery and therefore was classified as a pediatric failure in
this study. As expected, this was more frequent in the younger pa-
tients, and the difference was most pronounced when a cut‐off age of
10 years was considered. The limited lengthening potential of rela-
tively short implants is a critical issue in very young patients that
should be taken into consideration at the time of the treatment de-
cision and discussed with the parents of the patients.
F IGURE 5 Stanmore, Stryker, and Implantcast
prostheses all showed good implant survival
against mechanical failure. The Wright prosthesis
did worse [Color figure can be viewed at
wileyonlinelibrary.com]
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Overall, more modern implants showed relatively good out-
comes. Functional scores, measured according to the MSTS scoring
system, were on average good. Yet, the high need for further surgery,
high risk of infection (12%) and amputation (7%) during follow‐up,
warrant for further implant development.
5 | CONCLUSIONS
This study represents the largest database on expandable mega-
prostheses in the literature. It shows how this reconstructive tech-
nique has been used more frequently over the last decades and still
increases in popularity. Implants that are currently available in the
market show overall good implant survival and good functional
outcome, but repeat surgeries are frequent and major complications
still represent a concern. Noninvasive implants are associated with a
lower infection risk compared to implants that require invasive
procedures. Cemented and cementless stem fixation show compar-
able results in terms of implant survival against aseptic loosening.
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